Search:
Filter:
Post type:
Sort:
United States District Court District of New Jersey USA v Anise Kachadourian Judgment Filed May 2026 Read the document.
United States District Court District of New Jersey USA v Anise Kachadourian Plea Agreement Filed May 2023 Read the document.
United States District CourtDistrict of New Jersey USA v Anise Kachadourian Information Filed May 2023 Read the document.
United States District Court District of New Jersey USA v Jon Paul Dadaian Plea Agreement Filed May 2022 Read the document.
United States District Court District of New Jersey USA v Jon Paul Dadaian Information Filed May 2022 Read the document.
United States District Court District of New Jersey USA v Joel Lerner Judgment Filed June 2026 Read the document.
United States District Court District of New Jersey USA v Joel Lerner Plea Agreement Filed February 2023 Read the document.
United States District Court District of New Jersey USA v Joel Lerner Information Filed February 2023 Read the document.
How does mass compounding threaten patients? Drug compounding is intended to meet individual patient needs or temporarily bridge shortages – but the GLP-1 market has broken that model. Today, telehealth companies and compounding entities are mass-producing and marketing unapproved compounded GLP-1s. These unapproved versions put patient health and informed decision-making at risk because they are produced outside the FDA’s rigorous…
Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.